CLNN Logo

Clene Inc. (CLNN) 

NASDAQ
Market Cap
$44.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
128 of 776
Rank in Industry
85 of 433

Largest Insider Buys in Sector

CLNN Stock Price History Chart

CLNN Stock Performance

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy …

Insider Activity of Clene Inc.

Over the last 12 months, insiders at Clene Inc. have bought $685,891 and sold $22,516 worth of Clene Inc. stock.

On average, over the past 5 years, insiders at Clene Inc. have bought $6.12M and sold $796,474 worth of stock each year.

Highest buying activity among insiders over the last 12 months: MATLIN DAVID J (director) — $1.08M. Mortenson Mark (Chief Science Officer) — $97,432. Etherington Robert Dee (Chief Executive Officer) — $47,500.

The last purchase of 92,307 shares for transaction amount of $438,458 was made by MATLIN DAVID J (director) on 2024‑09‑30.

List of Insider Buy and Sell Transactions, Clene Inc.

2024-09-30Purchasedirector
92,307
1.4829%
$4.75$438,458+22.44%
2024-09-30PurchaseChief Executive Officer
10,000
0.1606%
$4.75$47,500+22.44%
2024-09-30PurchaseChief Science Officer
20,512
0.3295%
$4.75$97,432+22.44%
2024-05-01Sale10 percent owner
13,000
0.0092%
$0.40$5,148-32.89%
2024-04-30Sale10 percent owner
13,000
0.0098%
$0.42$5,416-31.94%
2024-04-24Sale10 percent owner
10,000
0.0076%
$0.33$3,278-12.02%
2024-04-09Sale10 percent owner
22,500
0.0172%
$0.39$8,675-19.26%
2023-11-10Purchasedirector
250,002
0.1815%
$0.41$102,501-17.33%
2023-06-26Purchasedirector
316,455
0.4161%
$0.80$253,164-45.16%
2023-06-26PurchaseChief Executive Officer
25,000
0.0333%
$0.81$20,250-45.16%
2023-06-16Purchase10 percent owner
7.5M
9.259%
$0.80$6M-47.83%
2023-06-16Purchasedirector
1.5M
1.8518%
$0.80$1.2M-47.83%
2023-06-16Purchasedirector
2.39M
2.9559%
$0.80$1.92M-47.83%
2023-06-16Purchasedirector
105,625
0.1304%
$0.80$84,500-47.83%
2022-11-02Purchasedirector
990,099
1.4746%
$1.01$1,000,000-7.69%
2022-11-02Purchasedirector
2.87M
4.2765%
$1.01$2.9M-7.69%
2022-11-02Purchasedirector
990,099
1.4746%
$1.01$1,000,000-7.69%
2022-11-02Purchasedirector
792,079
1.1797%
$1.01$800,000-7.69%
2022-11-02Purchasedirector
148,515
0.2212%
$1.01$150,000-7.69%
2022-08-17Purchase
47,662
0.0756%
$3.85$183,499-72.25%

Insider Historical Profitability

<0.0001%
MATLIN DAVID Jdirector
444491
5.5826%
$5.61220<0.0001%
Etherington Robert DeeChief Executive Officer
40149
0.5043%
$5.6121<0.0001%
Mortenson MarkChief Science Officer
28949
0.3636%
$5.6111
Ugwumba Chidozie10 percent owner
13018908
163.511%
$5.6120<0.0001%
Mosca Alisondirector
3238375
40.6724%
$5.6140<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$1.11B40.82.62M+0.05%+$559,401.170.02
Geode Capital Management$402.76M14.74946,532+54.69%+$142.4M0.03
Scoggin Management Lp$212.7M7.79500,000-33.33%-$106.35M61.37
Alyeska Investment Group L P$201.69M7.38474,130-71.89%-$515.91M1.24
Morgan Stanley$144.06M5.27338,6350%+$00.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.